Ying K. Tam

20.3k total citations · 15 hit papers
107 papers, 9.3k citations indexed

About

Ying K. Tam is a scholar working on Molecular Biology, Immunology and Infectious Diseases. According to data from OpenAlex, Ying K. Tam has authored 107 papers receiving a total of 9.3k indexed citations (citations by other indexed papers that have themselves been cited), including 68 papers in Molecular Biology, 49 papers in Immunology and 23 papers in Infectious Diseases. Recurrent topics in Ying K. Tam's work include RNA Interference and Gene Delivery (53 papers), Immunotherapy and Immune Responses (31 papers) and Immune Cell Function and Interaction (18 papers). Ying K. Tam is often cited by papers focused on RNA Interference and Gene Delivery (53 papers), Immunotherapy and Immune Responses (31 papers) and Immune Cell Function and Interaction (18 papers). Ying K. Tam collaborates with scholars based in United States, Canada and Germany. Ying K. Tam's co-authors include Barbara L. Mui, Pieter R. Cullis, Michael J. Hope, Thomas D. Madden, Paulo J.C. Lin, Drew Weissman, Norbert Pardi, Sam Chen, Akin Akinc and Steven M. Ansell and has published in prestigious journals such as Nature, Science and Proceedings of the National Academy of Sciences.

In The Last Decade

Ying K. Tam

104 papers receiving 9.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs

2019 1.2k citations Steven M. Ansell, Michael J. Hope et al. profile →
Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo**

2012 973 citations Steven M. Ansell, Barbara L. Mui et al. profile →
Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes

2015 688 citations Norbert Pardi, Steven Tuyishime et al. Journal of Controlled Release profile →
Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA

2012 548 citations Paulo J.C. Lin, Sam Chen et al. profile →
Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge

2017 267 citations Norbert Pardi, Hiromi Muramatsu et al. Nature Communications profile →
A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes

2022 218 citations Colleen Furey, Hiromi Muramatsu et al. profile →
A Multi-Targeting, Nucleoside-Modified mRNA Influenza Virus Vaccine Provides Broad Protection in Mice

2020 207 citations Barbara L. Mui, Ying K. Tam et al. Molecular Therapy profile →
Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies

2018 201 citations Norbert Pardi, Meagan McMahon et al. Nature Communications profile →
Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs

2021 183 citations István Tombácz, Hamna Shahnawaz et al. Molecular Therapy profile →
In vivo hematopoietic stem cell modification by mRNA delivery

2023 176 citations Laura Breda, Tyler E. Papp et al. profile →
PECAM-1 directed re-targeting of exogenous mRNA providing two orders of magnitude enhancement of vascular delivery and expression in lungs independent of apolipoprotein E-mediated uptake

2018 154 citations Hamideh Parhiz, Vladimir V. Shuvaev et al. Journal of Controlled Release profile →
Murine liver repair via transient activation of regenerative pathways in hepatocytes using lipid nanoparticle-complexed nucleoside-modified mRNA

2021 103 citations Ying K. Tam, Norbert Pardi et al. Nature Communications profile →
Single immunizations of self-amplifying or non-replicating mRNA-LNP vaccines control HPV-associated tumors in mice

2023 87 citations Hiromi Muramatsu, István Tombácz et al. profile →
Lipid nanoparticles (LNP) induce activation and maturation of antigen presenting cells in young and aged individuals

2023 65 citations Paulo J.C. Lin, Ying K. Tam et al. profile →
Development of an mRNA-lipid nanoparticle vaccine against Lyme disease

2023 46 citations Gunjan Arora, Thomas Hart et al. Molecular Therapy profile →

Peers

Ying K. Tam

IMMUN

GENET

ONCOL

Barbara L. Mui United States

Norbert Pardi United States

Tal Zaks United States

Thomas D. Madden Canada

Katalin Karikó United States

Jayesh A. Kulkarni Canada

Michael A. Barry United States

Nicolai V. Bovin Russia

Özlem Türeci Germany

Alan D. Frankel United States

Barbara L. Mui United States

Ying K. Tam

5.2k ×0.8

1.3k ×0.5

IMMUN

1.2k ×0.6

1.0k ×0.9

GENET

416 ×0.5

ONCOL

Citations per year, relative to Ying K. Tam Ying K. Tam (= 1×) peers Barbara L. Mui

Countries citing papers authored by Ying K. Tam

Since Specialization

Citations

This map shows the geographic impact of Ying K. Tam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ying K. Tam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ying K. Tam more than expected).

Fields of papers citing papers by Ying K. Tam

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ying K. Tam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ying K. Tam. The network helps show where Ying K. Tam may publish in the future.

Co-authorship network of co-authors of Ying K. Tam

This figure shows the co-authorship network connecting the top 25 collaborators of Ying K. Tam. A scholar is included among the top collaborators of Ying K. Tam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ying K. Tam. Ying K. Tam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gordy, James T., Mohamad‐Gabriel Alameh, Elizabeth Glass, et al.. (2025). iDC-targeting PfCSP mRNA vaccine confers superior protection against Plasmodium compared to conventional mRNA. npj Vaccines. 10(1). 34–34. 1 indexed citations

Phan, Anthony T., Mohamad‐Gabriel Alameh, Garima Dwivedi, et al.. (2025). An Il12 mRNA-LNP adjuvant enhances mRNA vaccine–induced CD8 T cell responses. Science Immunology. 10(108). eads1328–eads1328. 11 indexed citations

Atochina‐Vasserman, Elena N., Lisa C. Lindesmith, Carmen Mirabelli, et al.. (2024). Bivalent norovirus mRNA vaccine elicits cellular and humoral responses protecting human enteroids from GII.4 infection. npj Vaccines. 9(1). 182–182. 4 indexed citations

Wong, Teri Ann S., et al.. (2024). Impact of Metabolic States on SARS-CoV-2 Vaccine Responses in Mouse Models of Obesity and Diabetes. SHILAP Revista de lepidopterología. 5(1). 2–2. 1 indexed citations

Breda, Laura, Tyler E. Papp, Enrico Radaelli, et al.. (2024). An erythroid-specific lentiviral vector improves anemia and iron metabolism in a new model of XLSA. Blood. 145(1). 98–113.

Tilsed, Caitlin M., Tyler E. Papp, Kenji Kimura, et al.. (2024). IL7 increases targeted lipid nanoparticle–mediated mRNA expression in T cells in vitro and in vivo by enhancing T cell protein translation. Proceedings of the National Academy of Sciences. 121(13). e2319856121–e2319856121. 24 indexed citations

Arora, Gunjan, Thomas Hart, Emily Bettini, et al.. (2023). Development of an mRNA-lipid nanoparticle vaccine against Lyme disease. Molecular Therapy. 31(9). 2702–2714. 46 indexed citations breakdown →

Pajer, Krisztián, Annamária Marton, Drew Weissman, et al.. (2023). DELAYED INTRASPINAL DELIVERY OF MRNAS ENCODING A COMBINATION OF CYTOKINES AND GDNF PROMOTES MORPHOLOGICAL AND FUNCTIONAL RECOVERY FOLLOWING SPINAL CORD INJURY. IBRO Neuroscience Reports. 15. S177–S177. 1 indexed citations

Schiepers, Ariën, Allison J. Greaney, Trinity Zang, et al.. (2023). Molecular fate-mapping of serum antibody responses to repeat immunization. Nature. 615(7952). 482–489. 72 indexed citations

10.

Pardi, Norbert, Juan Manuel Carreño, George O’Dell, et al.. (2022). Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses. Nature Communications. 13(1). 4677–4677. 57 indexed citations

11.

Meel, Roy van der, Sam Chen, Josh Zaifman, et al.. (2021). Modular Lipid Nanoparticle Platform Technology for siRNA and Lipophilic Prodrug Delivery. Small. 17(37). e2103025–e2103025. 42 indexed citations

12.

Fornaguera, Cristina, Sejin Oh, Steven H.Y. Fan, et al.. (2021). Preclinical Assessment of a Gene-Editing Approach in a Mouse Model of Mitochondrial Neurogastrointestinal Encephalomyopathy. Human Gene Therapy. 32(19-20). 1210–1223. 13 indexed citations

13.

Parhiz, Hamideh, Vladimir V. Shuvaev, Norbert Pardi, et al.. (2018). PECAM-1 directed re-targeting of exogenous mRNA providing two orders of magnitude enhancement of vascular delivery and expression in lungs independent of apolipoprotein E-mediated uptake. Journal of Controlled Release. 291. 106–115. 154 indexed citations breakdown →

14.

Tam, Yuen Yi C., Sam Chen, Josh Zaifman, et al.. (2012). Small molecule ligands for enhanced intracellular delivery of lipid nanoparticle formulations of siRNA. Nanomedicine Nanotechnology Biology and Medicine. 9(5). 665–674. 36 indexed citations

15.

Jong, Susan de, et al.. (2010). The Immunostimulatory Activity of Unmethylated and Methylated CpG Oligodeoxynucleotide Is Dependent on Their Ability To Colocalize with TLR9 in Late Endosomes. The Journal of Immunology. 184(11). 6092–6102. 33 indexed citations

16.

Tam, Ying K., et al.. (2008). Lipid encapsulation promotes co-localization of methylated CpG ODN and TLR9 in late endosomes: A new model for the immunostimulatory activity of CpG DNA. Cancer Research. 68. 3802–3802. 2 indexed citations

17.

Raney, Sam G., Laura Sekirov, Ghania Chikh, et al.. (2008). The effect of circulation lifetime and drug-to-lipid ratio of intravenously administered lipid nanoparticles on the biodistribution and immunostimulatory activity of encapsulated CpG-ODN. Journal of drug targeting. 16(7-8). 564–577. 5 indexed citations

18.

Tam, Ying K.. (2003). Immunostimulatory Oligonucleotides: Ready for Immunotherapy Prime Time!. Journal of Hematotherapy & Stem Cell Research. 12(5). 467–471. 1 indexed citations

19.

Maki, Guitta, Hans-G. Klingemann, Jeffrey Martinson, & Ying K. Tam. (2001). Factors Regulating the Cytotoxic Activity of the Human Natural Killer Cell Line, NK-92. Journal of Hematotherapy & Stem Cell Research. 10(3). 369–383. 214 indexed citations

20.

Tam, Ying K., et al.. (1999). Immunotherapy of Malignant Melanoma in a SCID Mouse Model Using the Highly Cytotoxic Natural Killer Cell Line NK-92. Journal of Hematotherapy. 8(3). 281–290. 106 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact